In preclinical and clinical studies, finerenone has been shown to induce cardioprotective actions, to decrease levels of BNP and NT-proBNP and to reduce the risk of incident heart failure in patients with CKD and T2DM [5, 12]. This evidence concerns the gene NPPB and type 2 diabetes mellitus.